After its train wreck of manufacturing problems, Genzyme
Patients in the U.S. are now getting full supplies of Cerezyme, and international demand is expected to be met before the end of the year. Fabrazyme should be fully stocked during the first half of next year. Genzyme is on track to meet the deadlines set by the Food and Drug Administration's consent decree, including moving the filling step to services contracted from Hospira
But I still wouldn't buy.
The problem, as I see it, is that the upside doesn't justify the potential downside, especially when trying to figure out whether sanofi-aventis
But what happens if Sanofi walks away? Pfizer
That leaves what investors would be willing to pay for Genzyme's shares. Before Sanofi came in, that was about $54 per share. Surely Genzyme is worth more having proven that it's getting back on track. But one quarter doesn't make a turnaround, and the downside is still substantial if Sanofi pulls its offer.
Proceed with caution, Fools. I'll be watching this drama from the comfort of my living room sofa.
Interested in keeping track of Genzyme as it makes its comeback and fends off Sanofi's lowball bid? Click here to add it to My Watchlist, which will help you keep track of all our Foolish analysis on Genzyme.
Pfizer is a Motley Fool Inside Value selection. GlaxoSmithKline is a Motley Fool Global Gains pick. Motley Fool Options has recommended a diagonal call position on Johnson & Johnson, which is a Motley Fool Income Investor pick. Try any of our Foolish newsletter services free for 30 days.
True to its name, The Motley Fool is made up of a motley assortment of writers and analysts, each with a unique perspective; sometimes we agree, sometimes we disagree, but we all believe in the power of learning from each other through our Foolish community.